Thus, since anti-IL36R treatment downregulates similar genes as anti-IL17 or anti-IL23 therapy does, blockade of the IL-36 signaling pathway might be also similar effective as other biologicals for the treatment of psoriasis vulgaris patients. This evidence concerns the gene IL23A and psoriasis vulgaris.